Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 1.00 |
| ▸ | TGM2 | P21980 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 5/20 | 0.58 |
| ▸ | MAOA | P21397 | 4/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475283 | 1.00 | CES1 (1.00) | CES1TGM2ALDH1A1MAOBMAOA | |
| Isatin SCHEMBL28259465 | 0.93 | CES1 (0.86) | CES1TGM2ALDH1A1MAOBMAOA | |
| SCHEMBL7830942 | 0.91 | CES1 (0.83) | CES1TGM2ALDH1A1MAOBMAOA | |
| SCHEMBL23296092 | 0.87 | CES1 (0.77) | CES1TGM2ALDH1A1MAOBMAOA | |
| SCHEMBL31621242 | 0.87 | CES1 (0.77) | CES1TGM2ALDH1A1MAOBMAOA | |
| SCHEMBL14446594 | 0.84 | CES1 (0.72) | CES1TGM2ALDH1A1LRRK2CA1 | |
| SCHEMBL13973913 | 0.81 | CES1 (0.67) | CES1TGM2ALDH1A1LRRK2CA1 | |
| SCHEMBL1027756 | 0.80 | TGM2 (1.00) | CES1TGM2ALDH1A1MAOBMAOA | |
| SCHEMBL9472806 | 0.80 | CES1 (0.67) | CES1TGM2ALDH1A1LRRK2CA1 | |
| SCHEMBL14446692 | 0.80 | CES1 (0.67) | CES1TGM2ALDH1A1LRRK2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102245-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | THE UNIVERSITY OF TOLEDO (US) | 2024-05-16 | — | — | WO | claimed |
| CN-117304113-A | Synthesis method of 5- (trifluoromethoxy) -1H-indazole-3-carboxylic acid methyl ester | 南通大学 | 2023-12-29 | — | — | CN | claimed |
| CN-113912609-A | Preparation method of natural alkaloid tryptanthrin and derivative thereof | 江苏大学 | 2022-01-11 | — | — | CN | claimed |
| US-9486444-B1 | Anti-cancer compound | KING SAUD UNIVERSITY (SA) | 2016-11-08 | — | — | US | claimed |
| CN-102186826-B | Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides | HOFFMANN LA ROCHE | 2015-06-17 | — | — | CN | claimed |
| EP-2346833-B1 | DIAZONIUM-FREE METHOD TO MAKE AN INDAZOLE INTERMEDIATE IN THE SYNTHESIS OF BICYCLIC 5-(TRIFLUORMETHOXY)-1H-3-INDAZOLECARBOXYLIC ACID AMIDES | HOFFMANN LA ROCHE (CH) | 2013-03-27 | — | — | EP | claimed |
| US-8354536-B2 | Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1H-3-indazolecarboxylic acid amides | HOFFMAN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-20120259120-A1 | DIAZONIUM-FREE METHOD TO MAKE AN INDAZOLE INTERMEDIATE IN THE SYNTHESIS OF BICYCLIC 5-(TRIFLUORMETHOXY)-1H-3-INDAZOLECARBOXYLIC ACID AMIDES | ROCHE CAROLINA INC. | 2012-10-11 | — | — | US | claimed |
| US-8232412-B2 | Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1H-3-indazolecarboxylic acid amides | HOFFMANN-LA ROCHE INC. (US) | 2012-07-31 | — | — | US | claimed |
| CN-102186826-A | Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides | HOFFMANN LA ROCHE | 2011-09-14 | — | — | CN | claimed |
| EP-2346833-A1 | DIAZONIUM-FREE METHOD TO MAKE AN INDAZOLE INTERMEDIATE IN THE SYNTHESIS OF BICYCLIC 5-(TRIFLUORMETHOXY)-1H-3-INDAZOLECARBOXYLIC ACID AMIDES | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | claimed |
| WO-2010043515-A1 | DIAZONIUM-FREE METHOD TO MAKE AN INDAZOLE INTERMEDIATE IN THE SYNTHESIS OF BICYCLIC 5-(TRIFLUORMETHOXY)-1H-3-INDAZOLECARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-22 | — | — | WO | claimed |
| US-20100094011-A1 | DIAZONIUM-FREE METHOD TO MAKE AN INDAZOLE INTERMEDIATE IN THE SYNTHESIS OF BICYCLIC 5-(TRIFLUORMETHOXY)-1H-3-INDAZOLECARBOXYLIC ACID AMIDES | ROCHE CAROLINA INC. | 2010-04-15 | — | — | US | claimed |
| US-6114540-A | COMBINATORIAL LIBRARIES | ARQULE, INC. (US) | 2000-09-05 | — | — | US | claimed |
| US-12612389-B2 | Benzofuran-based N-acylhydrazone derivative and pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20260109674-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | THE UNIVERSITY OF TOLEDO (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4380921-B1 | D3 DOPAMINE RECEPTOR-SELECTIVE NEGATIVE ALLOSTERIC MODULATORS | US HEALTH (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-1995024395-A1 | QUINOLINE DERIVATIVES AS IMMUNOMODULATORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-14 | — | — | WO | disclosed |
| WO-1995013807-A1 | INDOLO[2,1-b]QUINAZOLINE-6,12-DIONE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | PATHOGENESIS CORPORATION (US) | 1995-05-26 | — | — | WO | disclosed |
| US-5198461-A | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259120-A1 | DIAZONIUM-FREE METHOD TO MAKE AN INDAZOLE INTERMEDIATE IN THE SYNTHESIS OF BICYCLIC 5-(TRIFLUORMETHOXY)-1H-3-INDAZOLECARBOXYLIC ACID AMIDES | CHRNA7, CHRNA5, CHRNA1 | CES1 567/4885TGM2 3904/4885ALDH1A1 987/4885 |
| US-20260109674-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | CHRM5, CHRM3, CHRNA3 | CES1 1731/4885TGM2 4686/4885ALDH1A1 2558/4885 |
| US-12612389-B2 | Benzofuran-based N-acylhydrazone derivative and pharmaceutical composition comprising same | TUBB3, TUBA1C, ACIN1 | CES1 2968/4885TGM2 2515/4885ALDH1A1 1031/4885 |
| US-20100094011-A1 | DIAZONIUM-FREE METHOD TO MAKE AN INDAZOLE INTERMEDIATE IN THE SYNTHESIS OF BICYCLIC 5-(TRIFLUORMETHOXY)-1H-3-INDAZOLECARBOXYLIC ACID AMIDES | CHRNA7, CHRNA5, CHRNA1 | CES1 567/4885TGM2 3904/4885ALDH1A1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.